Nektar Therapeutics
NASDAQ:NKTR

Watchlist Manager
Nektar Therapeutics Logo
Nektar Therapeutics
NASDAQ:NKTR
Watchlist
Price: 1.17 USD -8.59% Market Closed
Market Cap: 215.4m USD
Have any thoughts about
Nektar Therapeutics?
Write Note

Nektar Therapeutics
Operating Income

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Nektar Therapeutics
Operating Income Peer Comparison

Comparables:
JNJ
BMY
PFE
MRK
LLY

Competitive Operating Income Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Nektar Therapeutics
NASDAQ:NKTR
Operating Income
-$135.1m
CAGR 3-Years
32%
CAGR 5-Years
21%
CAGR 10-Years
-3%
Johnson & Johnson
NYSE:JNJ
Operating Income
$24.2B
CAGR 3-Years
-1%
CAGR 5-Years
7%
CAGR 10-Years
1%
Bristol-Myers Squibb Co
NYSE:BMY
Operating Income
$11.1B
CAGR 3-Years
5%
CAGR 5-Years
5%
CAGR 10-Years
13%
Pfizer Inc
NYSE:PFE
Operating Income
$13.1B
CAGR 3-Years
-17%
CAGR 5-Years
63%
CAGR 10-Years
-2%
Merck & Co Inc
NYSE:MRK
Operating Income
$21.7B
CAGR 3-Years
20%
CAGR 5-Years
10%
CAGR 10-Years
10%
Eli Lilly and Co
NYSE:LLY
Operating Income
$14.4B
CAGR 3-Years
25%
CAGR 5-Years
21%
CAGR 10-Years
15%

See Also

What is Nektar Therapeutics's Operating Income?
Operating Income
-135.1m USD

Based on the financial report for Jun 30, 2024, Nektar Therapeutics's Operating Income amounts to -135.1m USD.

What is Nektar Therapeutics's Operating Income growth rate?
Operating Income CAGR 10Y
-3%

Over the last year, the Operating Income growth was 10%. The average annual Operating Income growth rates for Nektar Therapeutics have been 32% over the past three years , 21% over the past five years , and -3% over the past ten years .

Back to Top